媒体聚焦丨央视国际（CGTN）就中国医药研发和海外出口采访管院王杉副教授
A new drug developed by a Chinese company is making waves in the global biotech industry. In late-stage trials, it outperformed Keytruda, the world's top-selling cancer medication.
In the trial, Ivonescimab nearly doubled the time patients lived without the disease worsening compared to Keytruda, which has generated over 130 billion U.S. dollars in sales for its American maker. The achievement has attracted widespread attention in the biotech industry.
WANG SHAN Associate Professor, School of Business Sun Yat-sen University "A key indicator we use is the number of research and development pipelines. This metric not only reflects our past investment in research and development, but more importantly, serves as a projection of our future research and development potential. Based on this indicator, China currently ranks second in the world, just behind the United States."
Professor Wang explains how China has distinct advantages in the field of pharmaceutical innovation.
WANG SHAN Associate Professor, School of Business Sun Yat-sen University "China has a well-established pharmaceutical supply chain. Additionally, our research and development costs are relatively low, thanks to abundant clinical resources and a large patient population."
Professor Wang acknowledges there's still a gap between China and the U.S. in terms of R&D pipelines, as China's numbers are about half of America's. But she highlights the wide room and increasing drive for growth and innovation.
采访原文：
https://news.cgtn.com/news/2025-03-17/VHJhbnNjcmlwdDgzNTU4/index.html
学者简介
99499www威尼斯副教授、硕士生导师、青年科学基金项目B类（原优秀青年科学基金）获得者。研究兴趣领域为医疗运营管理、数据驱动优化，研究成果发表于Management Science、Manufacturing & Service Operations Management等国内外权威刊物。曾获第九届高等学校科学研究优秀成果奖（人文社会科学）二等奖、POMS医疗运营管理分会最佳论文第一名等荣誉与奖励，目前担任中国管理科学与工程学会服务科学与工程分会委员、中国运筹学会医疗运作管理分会青年理事、中国运筹学会随机服务与运作管理分会青年理事。
